Saturday 17 October 2026 Export RKDA’s income statement to Excel — free account

Arcadia Biosciences, Inc.

Arcadia Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 3.71% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 35.9% and free cash flow grew 82.1%, each against the same quarter a year earlier.

0.16 0.04 −20.00%

Follow RKDA

Alert me

Market cap: $490.0K
P/E: 0.0×
Fwd P/E: −1.5×
Dividend yield: —
F-score: 3/9
Altman Z: −59.20
Beneish M: −1.84
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 32.18%

Capital & Financial Ratios $m

Market Cap 0.49

Revenue 4.75

Net Income (11.13)

Free Cash Flow (2.54)

Net Debt (4.18)

Current Ratio 3.49

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.51)

P/S ratio 0.10

P/B ratio 0.76

Past 5Y EPS Growth —

This Y EPS Growth 19.24%

Next Y EPS Growth 5.47%

Next Y revenue growth 58.50%

Next 5Y EPS Growth 49.05%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.04%

10-year low 10-year high

P/B against its own 10 years 30.37%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	12	4	5	4
Receivables	1	1	0	1
Inventory	1	1	1	1
Other	0	—	—	—
	15	9	6	6

	2023	2024	2025	Q'26
Payables	2	2	2	1
ST’ Debt	—	—	—	—
Other	0	0	0	0
	4	3	2	2

Compound Annual Growth %

	10y	5y	3y
Sales	(1.08%)	(9.57%)	(13.16%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(20.34%)	(32.04%)	(41.71%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	1	1	1	1	5
’24	1	1	2	1	5
’23	1	1	1	1	4
’22	3	4	2	(1)	7
’21	1	1	2	2	7
’20	0	0	0	7	8

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(2)	(2)	0	(1)	(5)
’24	(3)	(2)	(2)	(2)	(10)
’23	(3)	(5)	(3)	(4)	(15)
’22	(5)	(3)	(3)	(2)	(14)
’21	(5)	(6)	(8)	(7)	(26)
’20	(9)	(7)	(7)	(7)	(30)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(1)	(2)	0	0	(4)
’24	(3)	(2)	(2)	2	(5)
’23	(3)	(5)	(3)	(4)	(15)
’22	(4)	(3)	(3)	(2)	(13)
’21	(5)	(6)	(8)	(7)	(27)
’20	(10)	(8)	(7)	(7)	(33)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.11)	(2.09)	—	—	—
’25	1.90	(3.26)	0.62	(0.98)	(1.71)
’24	(1.78)	0.78	(1.18)	(2.98)	(5.17)
’23	(10.86)	0.61	(1.89)	(2.10)	(11.30)
’22	(8.00)	(6.80)	(4.80)	(6.31)	(25.65)
’21	4.40	(9.60)	(4.00)	(16.80)	(27.60)
’20	11.60	(41.60)	(24.00)	36.00	(18.80)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	688.00	144.00	105.80	72.80	92.00	38.88	10.36	2.60	1.85	1.76	Analyst estimates 2026–2028 Powerpack
	High	2,736.00	944.00	2,662.40	416.00	259.20	256.00	106.40	18.94	10.31	6.71
People
People	Employees	57	42	24	61	11	11	30	21	9	8
	Revenue/emp, $m	0.06	0.10	0.06	0.02	0.73	0.62	0.25	0.21	0.56	0.61
Income, $m
Income, $m	Revenue	3	4	1	1	8	7	7	4	5	5
	Gross margin, %	71.93	92.97	54.85	24.29	35.29	(28.44)	17.75	51.19	41.27	36.23
	EBT	(20)	(16)	(13)	(29)	(6)	(16)	(11)	(5)	(4)	(2)
	EBT margin, %	(614.77)	(389.49)	(920.08)	(2,469.72)	(76.55)	(237.94)	(145.78)	(119.47)	(85.41)	(47.98)
	Net income	(20)	(16)	(13)	(29)	(6)	(16)	(16)	(14)	(7)	(2)
	Depreciation	0	0	0	1	2	7	2	1	1	0
Per share, $
Per share, $	Revenue	57.44	74.69	15.54	7.35	32.27	12.74	12.38	3.60	3.70	3.55
	Earnings	(352.00)	(291.20)	(143.20)	(181.20)	(18.80)	(27.60)	(25.65)	(11.30)	(5.17)	(1.71)
	Cash flow	(307.30)	(259.09)	(144.70)	(108.10)	(121.36)	(48.62)	(23.33)	(12.36)	(7.06)	(3.46)
	Capex	(4.16)	(1.39)	(2.55)	(9.18)	(9.35)	(1.86)	1.42	0.09	3.17	0.55
	Free cash flow	(311.46)	(260.48)	(147.25)	(117.28)	(130.70)	(50.48)	(21.92)	(12.27)	(3.90)	(2.92)
	Book value	399.96	148.55	136.04	52.33	114.67	58.64	34.89	10.27	4.57	3.03
	Shares, m	0	0	0	0	0	1	1	1	1	1
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	12.53	2.89	8.16	29.83	3.14	3.26	0.90	0.81	1.60	0.56
	P/B	1.80	1.45	0.93	4.19	0.88	0.71	0.32	0.28	1.30	0.65
	EV/Sales	4.56	4.89	7.64	8.28	0.35	(0.95)	(1.86)	(1.78)	0.78	(0.36)
	EV/FCF	(0.84)	(1.40)	(0.81)	(0.52)	(0.09)	0.24	1.05	0.52	(0.42)	(1.61)
Cash, $m
Cash, $m	Operating cash flow	(17)	(14)	(14)	(17)	(30)	(26)	(14)	(15)	(10)	(5)
	Capex	0	0	0	(1)	(2)	(1)	1	0	4	1
	Free cash flow	(17)	(14)	(14)	(19)	(33)	(27)	(13)	(15)	(5)	(4)
Balance, $m
Balance, $m	Working capital	49	12	20	23	25	30	21	11	7	4
	Total debt	25	—	—	0	3	3	2	—	—	—
	Net debt	(25)	(13)	(22)	(25)	(22)	(29)	(21)	(12)	(4)	(5)
	Shareholders’ equity	22	8	13	8	29	31	21	13	6	4
Returns, %
Returns, %	ROA	(30.00)	(42.95)	(66.41)	(101.79)	(11.65)	(32.13)	(42.22)	(57.50)	(42.37)	(23.32)
	ROIC	0.00	0.00	0.00	0.00	(130.26)	(884.26)	(3,419.68)	(359.45)	(115.09)	0.00
	ROE	(62.87)	(104.00)	(129.48)	(272.50)	(25.25)	(49.07)	(59.03)	(83.21)	(74.37)	(45.14)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PAVS Paranovus Entertainment Technology Ltd.	$2.9M	— (loss-making)	— (loss-making)	−8.96% (below 0%: shrinking)	−582.47% (below 0%: shrinking)	+88.21% (above 0%: growing)	5.59%	0.00%	Compare
ORISF Oriental Rise Holdings Limited	$2.3M	—	—	—	—	−105.36% (below 0%: shrinking)	—	—	Compare
RGFC Real Good Food Company, Inc.	$2.2M	— (loss-making)	— (loss-making)	+47.98% (above 0%: growing)	n/m	+84.37% (above 0%: growing)	20.85%	(15.95%)	Compare
MEHA Functional Brands Inc.	$1.9M	— (loss-making)	—	+2.07% (above 0%: growing)	n/m	−209.98% (below 0%: shrinking)	59.89%	(70.59%)	Compare
ATPC Agape ATP Corporation	$1.7M	1.2×	—	−93.38% (below 0%: shrinking)	n/m	+77.69% (above 0%: growing)	86.13%	(4,021.90%)	Compare
CYAN Cyanotech Corporation	$1.7M	— (loss-making)	2.4×	+11.12% (above 0%: growing)	n/m	+204.00% (above 0%: growing)	42.38%	7.00%	Compare
BSFCD Blue Star Foods Corp.	$960.0K	14.2×	2.3×	−54.59% (below 0%: shrinking)	n/m	−123.09% (below 0%: shrinking)	55.80%	(29.04%)	Compare
STKH Steakholder Foods Ltd. Sponsored ADR	$670.0K	— (loss-making)	—	—	n/m	+35.62% (above 0%: growing)	0.00%	0.00%	Compare
RKDA Arcadia Biosciences, Inc.	$490.0K	— (loss-making)	— (loss-making)	−0.82% (below 0%: shrinking)	n/m	+82.11% (above 0%: growing)	43.73%	(34.37%)
Median of peers	$1.8M	—	—	−3.44%	—	+56.66%	42.38%	(15.95%)

All 71 Packaged Foods stocks →

Arcadia Biosciences, Inc. (RKDA) key facts

Concern: Arcadia Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 3.71% from fiscal 2024.
Concern: Arcadia Biosciences, Inc. reported a net loss of $2.3 million, or a loss of $1.71 per share, for fiscal 2025.
Arcadia Biosciences, Inc. (RKDA) is a Packaged Foods company in the Consumer Defensive sector, listed on Nasdaq.
As of October 16, 2026, RKDA traded at $0.16, a market capitalization of $490,000.00.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.1× sales.
Return on equity was −45.1% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −59.20 (distress zone) for fiscal 2025.